This profile of Carl Icahn and his company-raiding ways is not from The Onion, but from Forbes “The Billionaires Issue”:
. . . saw the company as part beauty, part beast. The attraction was its rare-disease drug division: Therapies like Cerezyme (which treats Gaucher’s disease) were cheap to make ($3,000, he guesses, for a year’s worth) and expensive to buy ($300,000 for an annual dose); if patients didn’t take them, they’d die. Here was a perfect monopoly with margins likely on the order of 95%.
The ugly side of Genzyme [one would have thought there could not be an uglier side than what is represented in the preceding paragraph]: a jumble of noncore drugs, including less specialized oncology treatments, and surgical and diagnostics products with no connection to the lucrative rare-disease therapeutics.
Good to know: a “perfect monopoly” is one in which people die if they can’t play your very expensive game.
Bertoni, Steven. (2011, March 28). The Raider’s Radar: How does Carl Icahn choose his targets, then pounce? A rare look inside his head. Forbes, 110–116.